Table 3. Care received by surveyed women due to injection of depot medroxyprogesterone acetate (DMPA) from health extension workers (HEWs) and by community-based reproductive health agents (CBRHAs), Ethiopia, 2008–2009.

Characteristic	13 week questionnaire				6 month questionnaire
	HEW clients (%)	CBRHA clients (%)	P		HEW clients (%)	CBRHA clients (%)	P
	(n = 398)	(n = 526)			(n = 286)	(n = 498)
Satisfaction
With DMPA	98.4	99.2	0.26		100.0	98.8	0.06
With provider	97.6	95.6	0.10		97.6	96.2	0.29
Provider services
Gave written appointment reminder	98.9	92.8	< 0.01		100.0	96.4	< 0.01
Explained potential side-effects	98.1	98.8	0.40		98.9	98.1	0.41
Discussed STI/HIV/AIDS	95.9	95.1	0.58		98.9	97.6	0.20
Explained that DMPA does not protect against HIV	97.5	97.1	0.68		98.9	99.4	0.47
Offered condoms in addition	58.3	75.8	< 0.01		72.7	80.4	0.01
Naming of side-effects from DMPA
Irregular bleeding	35.9	34.9	0.75		31.5	43.2	< 0.01
Heavy bleeding	31.7	19.9	< 0.01		33.9	31.2	0.43
Spotting	10.3	12.3	0.36		12.2	15.3	0.24
Amenorrhoea	18.2	38.7	< 0.01		20.3	41.5	< 0.01
Headache	16.4	10.3	< 0.01		16.8	10.8	0.02
Weight gain	4.5	11.7	< 0.01		9.4	21.4	< 0.01
Weight loss	1.3	1.0	0.61		0.7	2.0	0.15
Irritability	3.4	8.8	< 0.01		1.7	6.9	< 0.01
Hair loss	5.8	11.5	< 0.01		10.1	19.1	< 0.01
Naming of side-effects requiring visit to health centre
Severe headache	38.5	31.1	0.03		28.1	30.5	0.47
Very heavy bleeding	61.3	53.3	0.02		66.3	57.5	0.02
Pregnancy	21.4	16.4	0.07		31.2	32.8	0.66
Chest pain	4.3	5.8	0.32		2.1	1.6	0.65

AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; STI, sexually-transmitted infection.